Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stake in Alkermes plc $ALKS

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Alkermes plc (NASDAQ:ALKS) by 39.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,530 shares of the company’s stock after buying an additional 55,364 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Alkermes were worth $5,442,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Alkermes by 2.3% in the 2nd quarter. State Street Corp now owns 8,208,256 shares of the company’s stock worth $234,838,000 after buying an additional 185,586 shares during the last quarter. Baker BROS. Advisors LP increased its holdings in Alkermes by 26.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 8,091,351 shares of the company’s stock worth $242,741,000 after acquiring an additional 1,680,748 shares during the last quarter. American Century Companies Inc. raised its position in shares of Alkermes by 20.2% in the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company’s stock valued at $131,924,000 after purchasing an additional 740,248 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Alkermes by 19.4% during the third quarter. Dimensional Fund Advisors LP now owns 3,697,996 shares of the company’s stock worth $110,925,000 after acquiring an additional 601,359 shares in the last quarter. Finally, Commodore Capital LP lifted its holdings in Alkermes by 26.4% during the 3rd quarter. Commodore Capital LP now owns 3,096,754 shares of the company’s stock worth $92,903,000 after purchasing an additional 646,754 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP David Joseph Gaffin sold 2,034 shares of Alkermes stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $34.57, for a total value of $70,315.38. Following the completion of the sale, the executive vice president directly owned 233,592 shares in the company, valued at approximately $8,075,275.44. This trade represents a 0.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Todd Nichols sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the transaction, the senior vice president directly owned 109,769 shares of the company’s stock, valued at $3,293,070. The trade was a 5.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 159,468 shares of company stock worth $5,433,699. Corporate insiders own 4.59% of the company’s stock.

Alkermes Price Performance

Shares of NASDAQ ALKS opened at $34.14 on Wednesday. The firm has a 50-day moving average of $31.37 and a 200 day moving average of $30.92. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.48. The stock has a market cap of $5.68 billion, a P/E ratio of 23.87 and a beta of 0.44.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Saturday, February 14th. The company reported $0.29 earnings per share for the quarter. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million for the quarter. Research analysts expect that Alkermes plc will post -0.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. HC Wainwright reissued a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a report on Thursday, February 26th. Piper Sandler cut their target price on Alkermes from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Tuesday, March 24th. Royal Bank Of Canada reduced their price objective on Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Wolfe Research began coverage on shares of Alkermes in a research note on Monday, February 23rd. They issued an “outperform” rating and a $45.00 target price on the stock. Finally, Zacks Research raised Alkermes from a “strong sell” rating to a “hold” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.